Search results for: 'quantitative drug analysis research'

Sequencing technologies have evolved over the years to harness the value of the human genome and dive deep into DNA and RNA sequences which offer immense knowledge of human biology. From Sanger sequencing to next-generation sequencing, technologies and chemistries have improved/advanced to reduce costs and ensure faster timelines. NGS has integrate...

Single-cell analysis can diagnose a condition in heterogenous cell population samples by studying genomics, transcriptomics, proteomics, metabolomics, and other cellular interactions in cells. It helps to understand a tumor microenvironment better and develop drugs based on newly uncovered knowledge of various types of tumors. The rich data provide...

The discovery of new drug targets for diseases with unmet medical needs has long been hindered by the complexity of processing and interpreting massive volumes of biological data. The increasing volume and veracity of clinical and research data compels the use of enabling tools and technologies, such as cloud computing, AI, machine learning, natura...

Targeted drug delivery is gaining traction owing toward significant demand for improvement in the drug delivery efficiency as well as the need to mitigate potential side-effects, which can occur due to drug accumulation. The concept of targeted drug delivery is not new, the technology started gaining pace with the advent of nanotechnology and bioco...

For a long time, drug discovery followed the same path and used conventional analysis methods for proposed targets. Today, changes in technology and the ability to study omics are transforming drug development. Personalized therapy is on the rise and promises to be more effective and efficient in addressing challenges. With growing interest in ...

05 Aug 2024  |  Global  |  Technology Research

CGT Research Outlook and Technology Growth Opportunities

CGT Landscape Assessment

Infographics

×

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, a...

This research service provides revenue forecasts for CROs globally, by phase and market type, R&D spending trends of pharmaceutical and biotechnology companies and pipeline drugs and clinical trial trends by phase and region. For the purpose of this research service, the U.S. CRO markets include revenues derived from the preclinical and clinical...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....